Abstract: Provided are methods of treating skin with at least two alternating treatment modalities to improve the health and/or diminish signs of aging. Some methods according to the present invention may comprise topically applying at least two separate compositions, in a sequential, rotating, or alternating fashion to overcome adaptation, tolerance, or sensitization phenomena.

Abstract: A skin-protection composition is shown that comprises stilbenoid(s) and/or stilbenoid-containing extract(s) obtained from Dendrobium plants, such as Dendrobium officinale and Dendrobium nobile for the management of melanogenesis, skin-darkening and skin-aging. More particularly, the usage of Dendrobium ingredients and stilbenoids is shown to reduce the formation of melanin in melanocytes. The usage of Dendrobium ingredients and stilbenoids is also shown to reduce the generation of reactive oxygen species and oxidative free radicals. The use of Dendrobium-derived extracts or ingredients or stilbenoids is shown in the formulation of skin-protection, skin-whitening and/or anti-skin aging products.

Abstract: The antimicrobial foaming composition of the present invention comprises a cationic active ingredient, a cationic compatible surfactant, a foam booster, a foam structure enhancing agent, dermal adjuvants, and a carrier. The present antimicrobial compositions are free of the antimicrobial agents triclosan (i.e., 2,4,4?-trichloro-2?hydroxy-diphenylether) and lower alcohols. They are also free of anionic surfactants. The foaming compositions have rapid cidal activity, provide stable, copious foam, and exhibit enhanced tissue (e.g. skin) compatibility.

Abstract: The invention relates to a surfactant composition including at least one compound of formula (I): in which each of the radicals Z is a hydrogen atom or (Z1); at least one compound of formula (IV); one compound of formula (V); and one compound of formula (VI). The invention also relates to a method for preparing said composition and to the use thereof in cosmetics.

Abstract: A method for shaping keratin fibers comprising: providing a crosslinking composition, wherein the crosslinking composition comprises: an active agent, wherein the active agent is a amine or diamine; a photocatalyst; a cosmetically acceptable carrier; and applying the crosslinking composition to keratin fibers, mechanically shaping the keratin fibers with an appliance or implement, and exposing the composition to electromagnetic radiation having a wavelength of from about 300 nm to about 750 nm. Also a related composition, use, kit and process.

Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C8-C24 alcohol ester of a carboxylic acid.

Abstract: The present invention relates to a novel use of fucosterol and, more specifically, to a composition for skin whitening or composition for skin moisturizing, which is characterized by containing fucosterol. Fucosterol of chemical formula 1 below has an excellent whitening effect of inhibiting melanin generation and tyrosinase activity, and thus can be used as an active ingredient of a cosmetic composition for whitening, a food composition, or a pharmaceutical composition.

Abstract: Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound, a calcium channel blocker, an immunosuppressive component, an anti-hypertensive, a hormone, a steroid, and an enzyme inhibitor into a chamber. The methods may comprise milling and mixing the NSAID compound, the calcium channel blocker, the immunosuppressive component, the anti-hypertensive, the hormone, the steroid, and the enzyme inhibitor into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form the formulation.

Abstract: Provided is an oil-based cosmetic comprising a siliconized polysaccharide compound, silicone emulsifier, organic modified clay mineral, carbonic acid ester, and wax. According to the present invention, a spinnable oil-based composition having exceedingly excellent adherability can be obtained by using a specific siliconized polysaccharide compound, silicone emulsifier, organic modified clay mineral, carbon dioxide ester, and wax, and if this composition is used in an eyelash cosmetic material, it is possible to obtain an eyelash cosmetic material that has excellent adherability, has an excellent long-lash effect without adding fibers, and is capable of imparting a natural finished look.

Abstract: A composition for a thinning agent to reduce the viscosity of a traditional gel or gel polish includes at least one monomer and a photoinitiator. The thinner can reduce the viscosity of a gel polish that has thickened, and allow for easy application of the gel to the nails. Aspects of the thinner can cause a ultra-violet curable gel or gel polish, using a ultra-violet light, to cure using a ultra-violet light emitting diode light source, when the thinner is added to the gel. The thinner is versatile and can be added to any gel polish or traditional gel to extend the life of the gel.

Abstract: Cosmetic preparations and formulations are described, comprising high concentration (from at least 75% to at least 95%) of thermal mineral waters within the aqueous portion of the formulation. In preferred embodiments, the thermal mineral waters are rendered more bioavailable by pre-fermentation with a microorganism such as the yeast Saccharomyces cerevisiae. Formulations are also described in which at least a portion of the thermal mineral water is incorporated into phospholipid liposomes.

Abstract: A hair care composition that prevents hair loss and stimulates hair growth is disclosed. The hair care composition of the present invention comprises natural ingredients including one and/or more carrier oils, one and/or more essential oils, and fragrance oil. The preferred embodiment including Shea Butter, Extra Virgin Olive oil, Jojoba oil, Vanilla fragrance oil, Peppermint essential oil, Lavender essential oil, Tea Tree essential oil, Clary Sage essential oil, and Rosemary essential oil is provided.

Abstract: Formulations to treat skin discoloration via a multi-modal approach are provided in which select ingredients work together to effectively brighten skin and treat hyperpigmentation. An example formulation includes a first anti-melanin agent, a second anti-melanin agent, an anti-inflammatory agent, a sun protection agent, and an anti-oxidant. In one aspect, the first anti-melanin agent comprises a bidens pilosa extract, the second anti-melanin agent comprises a rheum rhaponticum extract, the anti-inflammatory agent comprises a Vitamin E compound, the sun protection agent comprises zinc oxide and titanium dioxide, and the antioxidant comprises a thermus thermophilus ferment extract.

Abstract: A veterinary pharmaceutical composition, including at least one active veterinary pharmaceutical substance which is selected among gonadorelin and gonadorelin analogs as well as salts of gonadorelin and of the gonadorelin analogs, is provided. The composition includes a liposome-free matrix which delays the release of the active veterinary pharmaceutical substance from the composition, which matrix includes a basic material which is selected from the group consisting of natural and synthetic triglycerides, vegetable oils, diacylpropanediols, diacylbutanediols and mixtures of these substances, the veterinary pharmaceutical composition including no biodegradable polymer.

Abstract: Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug.

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

Abstract: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a teat seal formulation including a metal salt in a glyceride-containing gel base into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.

Abstract: Contact lenses are described that include particles of polymer fiber mat incorporated into a polymer lens wherein the polymer fiber mat is formed by electrospinning a prepolymer solution. Methods for making the contact lenses with improved oxygen permeability are also described. Methods for making the contact lens with optional therapeutic drug delivery and refractive correction are also described.

Abstract: A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, where an immune response is induced in a patient in need thereof.

Abstract: A method of making a dry powder pharmaceutical composition comprising: providing inactive ingredient particles; providing a micronized active ingredient; mixing the inactive ingredient particles with surface-modified nanoparticles to provide an inactive ingredient comprised of particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and/or mixing the micronized active ingredient with surface-modified nanoparticles to provide a micronized active ingredient comprised of particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and then mixing the micronized active ingredient with the inactive ingredient; the dry powder compositions made by the method; a use of said composition for the manufacture of a medicament for being delivered to the lungs of a mammal by administering a therapeutic amount of the dry powder pharmaceutical composition, and a dry powder inhalation device comprising a mouth piece, a powder containment system, and the dry po

Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Abstract: The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.

Abstract: Non-psychoactive packaged frozen cubes of cannabis juice purée are provided. First, raw cannabis material is collected. Next, the cannabis material is blended with water, fruit juice, or vegetable juice and thickening agent to form cannabis juice purée. Next, the purée is poured into molds having an identical size and shape. Non-decarboxylated high concentrate cannabis extract is optionally added to increase potency. Next, the tray is frozen to obtain frozen cubes of cannabis juice purée. Next, the cubes are removed from the tray and packaged in a vacuum sealed bag. A dispensary can store the package in a freezer until distribution. The package includes a label describing amounts and types of cannabinoids present in each cube. The cubes are non-psychoactive and do not include decarboxylated cannabinoids. A consumer opens the package and deposits a desired amount of cubes into a blender with other ingredients to form a beverage with non-decarboxylated cannabinoids.

Abstract: Packaged frozen cubes of cannabis juice purée having decarboxylated cannabinoids are provided. First, raw cannabis material is collected. Next, the cannabis material is blended with water, fruit juice, or vegetable juice and thickening agent to form cannabis juice purée. Next, the purée is poured into molds having an identical size and shape. Decarboxylated/non-decarboxylated high concentrate cannabis extract or decarboxylated cannabis infusion is added to the molds. Next, the tray is frozen to obtain frozen cubes of cannabis juice purée. Next, the cubes are removed from the tray and are packaged in a vacuum sealed bag. A dispensary can store the package in a freezer until distribution. The package includes a label describing amounts and types of cannabinoids present in each cube. A consumer opens the package and deposits a desired amount of cubes into a blender along with other ingredients to form a beverage with non-decarboxylated cannabinoids.

Abstract: The invention pertains to thermosensitive liposomes encapsulating nanoparticles. In certain embodiments, the thermosensitive liposomes of the invention disrupt when heated at gel-to-liquid crystalline phase transition temperature (Tm) or above Tm, wherein the liposome comprises a thermosensitive lipidic membrane encapsulating nanoparticles. The nanoparticles used in the invention comprise an inorganic core the largest dimension of which is less than about 100 nm that is fully coated with an agent responsible for the presence of an electrostatic charge below ?20 mV or above +20 mV at the surface of the nanoparticle, the electrostatic charge being determined by zeta potential measurements in an aqueous medium between pH 6 and 8, for a concentration of nanoparticles in suspension in the aqueous medium varying between 0.2 and 8 g/L. The invention also relates to pharmaceutical and diagnostic compositions comprising the thermosensitive liposomes as well as to their uses.

Abstract: Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.

Abstract: A method of making a sustained release microsphere formulation, wherein the release rate of a bioactive ingredient is manipulated by controlling the crystallinity of said bioactive ingredient, includes the steps of combining the active ingredient and an encapsulating polymer in at least one solvent, or mixtures thereof, to form a dispersed phase and processing the dispersed phase without filtering, filtering the combined dispersed phase with a hydrophobic or a hydrophilic filter, or filtering the active ingredient and encapsulating polymer individually with a hydrophobic or hydrophilic filter before combining them to form the dispersed phase. The dispersed phase is then combined with a continuous phase to form the microsphere formulation.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.

Abstract: A method and apparatus for continuous removal of sub-micron sized particles and other materials attached thereto such as cancer cells and bacteria from blood and other liquids. A centrifuge rotor having a curved shape is offset on a spinning rotor base and creates contiguous areas of low to high centrifugal force depending on the distances from the axis of the rotor base. This creates a density gradient field that separates materials of different densities input to the centrifuge that exit via different outputs. A monitor detects components of the fluid that are mixed with the particles before they exit the centrifuge. If there are any unwanted components detected with the particles logic circuitry changes the speed of rotation of the rotor, and the flow rate of pumps inputting and removing separated fluid and particles to and from the centrifuge until there are no unwanted components in the fluid exiting with the particles from the centrifuge.

Abstract: A nano-composition and a method of using the composition. The composition includes nanoparticles. Each nanoparticle includes a shell encapsulating lycopene. The shell includes oligomerized (?)-epigallocatechin-3-O-gallate (OEGCG) electrostatically bonded to chitosan. The method of using the composition includes administering the nano-composition to a human being.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.

Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Abstract: The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate.

Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.

Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Abstract: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.

Abstract: This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.

Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a pediatric epilepsy or epilepsy-related syndrome comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating pediatric epilepsy or pediatric epilepsy-related syndromes.

Abstract: Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as TAN-2483B and their use for treating cancer, osteoporosis, Type 2 diabetes, or immune diseases.

Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.

Abstract: A method of using a composition including dihydroquercetin, as well as optionally ?-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.